6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $42M | -$11M | 0.0% | -27.2% | -$13M | — | $6M |
| 2024 | $37M | -$18M | 0.0% | -46.1% | -$10M | — | $6M |
| 2023 | $34M | -$20M | 0.0% | -66.6% | -$25M | — | $1M |
| 2022 | $29M | -$640000 | 0.0% | -64.8% | -$16M | — | $17M |
| 2021 | $24M | -$38M | 0.0% | -104.8% | — | — | $25M |
| 2020 | $19M | -$11M | 0.0% | -51.0% | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $10M | -$5M | 0.0% | -42.8% | -$75000 | — | $6M |
| Dec '25 | $17M | $6M | 0.0% | 26.7% | -$2M | — | $6M |
| Sep '25 | $7M | -$7M | 0.0% | -89.8% | -$4M | — | $3M |
| Jun '25 | $9M | -$5M | 0.0% | -56.2% | -$3M | — | $7M |
| Mar '25 | $9M | -$4M | 0.0% | -52.9% | -$4M | — | $2M |
| Dec '24 | $13M | -$1M | 0.0% | -13.6% | -$1M | — | $6M |
| Sep '24 | $9M | -$6M | 0.0% | -55.0% | -$1M | — | $3M |
| Jun '24 | $8M | -$257000 | 0.0% | -64.7% | -$5M | — | $4M |
| Mar '24 | $8M | -$10M | 0.0% | -69.1% | -$3M | — | $4M |
| Dec '23 | $11M | $4M | 0.0% | -36.5% | -$9M | — | $1M |
| Sep '23 | $9M | -$6M | 0.0% | -51.9% | -$2M | — | $3M |
| Jun '23 | $6M | -$10M | 0.0% | -148.8% | -$10M | — | $4M |
| Mar '23 | $9M | -$7M | 0.0% | -62.9% | -$4M | — | $1M |
| Dec '22 | $10M | -$3M | 0.0% | -55.4% | -$8M | — | $17M |
| Sep '22 | $4M | -$3M | 0.0% | -84.2% | -$6M | — | $28M |
| Jun '22 | $4M | -$850000 | 0.0% | -139.4% | — | — | $32M |
| Mar '22 | $10M | $6M | 0.0% | -31.9% | — | — | $22M |
| Dec '21 | $9M | -$15M | 0.0% | -20.5% | — | — | $25M |
| Sep '21 | $4M | -$16M | 99.1% | -371.6% | -$1M | — | $2M |
| Jun '21 | $6M | -$4M | 0.0% | -63.0% | — | — | — |
How the market has priced BFRI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Biofrontera Inc.'s revenue has grown 17.2% per year. These are computed facts, not advice.
As of FY2025, Biofrontera Inc. reported — of total debt against $6M of cash.
In FY2025, gross margin was —, operating margin -27.2%, and net margin -25.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.